Weiss Lawrence T. - 15 Jul 2026 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Reporting relationship: SVP, Chief Legal Officer
Issuer ticker: ANGO
Reported as of: 15 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jul 2026, 20:06:02 UTC
Prior SEC filing: 22 Oct 2025
Next SEC filing: 21 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Lawrence Weiss

Key filing fact

Weiss Lawrence T. filed Form 4 for ANGIODYNAMICS INC (ANGO) on 22 Jul 2026.

Key facts

This page summarizes Weiss Lawrence T.'s Form 4 filing for ANGIODYNAMICS INC (ANGO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Jul 2026, 20:06.

Change

Previous filing in this sequence was filed on 22 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001930293 Primary reporting owner

Weiss Lawrence T

Relationship: SVP, Chief Legal Officer
Address: 14 PLAZA DRIVE, LATHAM
Signature: /s/ Lawrence Weiss
Signature date: 22 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANGO transaction

Common Stock

Award

Transaction value
Shares: +21,288
Change %: +23%
Price: $0.000000^*
Shares after: 112,618
Date: 15 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANGO transaction Derivative

Performance Right

Award

Transaction value
Shares: +21,288
Change %
Price: $0.000000^*
Shares after: 21,288
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,288
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The acquisition of 21,288 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 21,288 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

Footnote F2

Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.